Microbiologists Nigel and Sue Plummer established Cultech Ltd in 1994 with the vision for a company that had research at its heart.
The company now employs a team of 20 research scientists and spends around £500,000 a year on research into the use of probiotics and other nutritional compounds to support health. This research is ongoing and we currently have two major studies in the field.
Cultech is an internationally recognised innovator and premium quality manufacturer within the nutritional supplement industry, with specific expertise and experience in probiotics.
The scientists at Cultech have more than 30 years’ experience of the discovery and development of probiotic bacteria and the production of probiotic products, both as stand-alone probiotics and in combination with other nutrients. They have spent the last 20 years undertaking clinical research to prove the effectiveness of the Lab4 consortia of probiotic strains, which are now supported by robust and rigorous testing and extensive research in vitro, in vivo and in human clinical trials.
Cultech Ltd is licensed by the MHRA to produce probiotics for clinical studies. Probiotics are different from other supplements in that bacterial strain differences mean that benefits can be specific to an individual product. Ongoing research and a detailed understanding of the developments in the probiotic industry are both necessary to stay ahead of the game. Approval to give probiotics to almost 500 healthy newborn babies for the Swansea Baby Study is a testament to the quality and safety of the Lab4 products.
The strains of bacteria used in the Lab4, Lab4B and Lab4P consortia are lactic acid bacteria (LAB) and bifidobacteria that have been isolated from the gut microbiota of healthy humans and then screened for appropriate probiotic characteristics, ranging from resistance to stomach and bile acids, to robust capability for large-scale in-vitro cultivation and commercialisation.
The Lab4 consortium combines four strains of lactic acid bacteria and bifidobacteria isolated from human gut microbiota – two strains of Lactobacillus acidophilus, one Bifidobacterium animalis subsp. lactis and Bifidobacterium bifidum.
The Lab4b consortium also combines four strains of lactic acid bacteria and bifidobacteria that have been specifically designated to reflect the gut of newborn babies and infants. This combination contains the same Bifidobacterium animalis subsp. lactis and Bifidobacterium bifidum as the Lab4 consortium, but contains Lactobacillus salivarius and Lactobacillus paracasei instead of the two Lactobacillus acidophilus strains.
The Lab4P consortium combines five strains – the four Lab4 strains with Lactobacillus plantarum.
Since their inception, the Lab4 consortia have been the subject of more than 20 major human clinical trials as well as over 100 basic and mechanistic scientific investigations. Most of this work has been published in peer-reviewed journals.
These consortia have also been used by many popular brands of probiotic all over the world to benefit many thousands of people.